Jade Biosciences (JBIO)

• Market cap: $796M
• 1 day: -5.23%
• 5 days: 3.53%
• 1 month: 23.02%
• 3 months: 79.33%
• 6 months: 121.4%
• Year to date: 13.98%
• 1 year: -82.06%
• 5 years: -97.98%
• 10 years: -97.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.